Frequently Asked Questions about Biogen Inc. (BIIB)

Name: Biogen Inc. (BIIB) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Biogen Inc. (BIIB) do?

Accepted Answer

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaq...

Question 2

Is Biogen Inc. (BIIB) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of BIIB reveals an Altman Z-Score of 3.17 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($9.81B most recent), help investors decide if BIIB fits their risk profile.

Question 3

What is the current P/E ratio for BIIB?

Accepted Answer

As of the latest trading session, Biogen Inc. (BIIB) has a trailing P/E ratio of 19.47.

Question 4

Who is the CEO of Biogen Inc.?

Accepted Answer

The current Chief Executive Officer of Biogen Inc. is Christopher A. Viehbacher.

Question 5

What was BIIB's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Biogen Inc. reported annual revenues of $9.81B (2025), $9.68B (2024), $9.84B (2023), $10.17B (2022), $10.98B (2021) respectively.

Question 6

Does BIIB pay a dividend?

Accepted Answer

Biogen Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does BIIB have?

Accepted Answer

In its latest reporting period, Biogen Inc. generated $2.05B in Free Cash Flow against a total debt load of $6.95B.

Question 8

What is the Price-to-Book (P/B) ratio of Biogen Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Biogen Inc. (BIIB) is currently 1.38.

Question 9

What is the Price-to-Sales (P/S) ratio of BIIB?

Accepted Answer

Based on trailing twelve-month data, Biogen Inc. (BIIB) trades at a Price-to-Sales (P/S) ratio of 2.57.

Question 10

What is Biogen Inc.'s Return on Equity (ROE)?

Accepted Answer

Biogen Inc. (BIIB) has a Return on Equity (ROE) of 7.28%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	2.2B	290.8M	-153.8M	2.1B	1.8B
2024-12	2.9B	291.2M	-359.8M	2.5B	2.2B
2023-12	1.5B	264.2M	-311.4M	1.2B	971.6M
2022-12	1.4B	254.1M	-240.3M	1.1B	889.9M
2021-12	3.6B	238.6M	-258.1M	3.4B	3.1B

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	2.2B	290.8M	-153.8M	2.1B	1.8B
2024-12	2.9B	291.2M	-359.8M	2.5B	2.2B
2023-12	1.5B	264.2M	-311.4M	1.2B	971.6M
2022-12	1.4B	254.1M	-240.3M	1.1B	889.9M
2021-12	3.6B	238.6M	-258.1M	3.4B	3.1B